Last $3.19 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:30 PM 01/3/14 All times are local (Market data is delayed by at least 15 minutes).

zeltia sa (ZLIXF) Key Developments

Zeltia SA Presents at European Smallcap Event, Apr-07-2014

Zeltia SA Presents at European Smallcap Event, Apr-07-2014 . Venue: Pullman Tour Eiffel, Paris, France.

The Zeltia Group Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2013

The Zeltia Group reported earnings results for the fourth quarter and year ended December 31, 2013. For the period, the reported loss attributable to equity-holders of the parent company of EUR 2.77 million, compared to a loss attributable to equity-holders of the parent company of EUR 1.95 million for the same quarter ended December 31, 2012. Total revenue was EUR 34.54 million, compared to EUR 29.86 million for the same quarter ended December 31, 2012. Income attributable to equity-holders of the parent company for the year ended December 31, 2013 was EUR 11.32 million, compared to EUR 6.59 million for the year ended December 31, 2012. Total revenue for the year ended December 31, 2013 was EUR 164.68 million, compared to EUR 161.78 million for the year ended December 31, 2012.

Zeltia SA Reports Earnings Results for the Year Ended December 31, 2013

Zeltia SA reported earnings results for the year ended December 31, 2013. For the year, the company reported EBITDA of EUR 23.8 million increased by 16.6%. The groups operating cash flow totaled EUR 16.1 million against EUR 6.6 million a year ago. Net attributable profit of EUR 11.3 million against EUR 6.5 million a year ago. Revenues totaled EUR 142 million against EUR 138 million a year ago, of which EUR 79 million were generated from the biopharmaceutical segment and EUR 62 million from consumer chemicals. EBITDA amounted to EUR 23.8 million against EUR 20.4 million a year ago. Net sales of Yondelis increased by 10% in 2013. The group also said it managed to strengthen its leverage and debt coverage ratio, as higher cash flow and results reduced total net debt by nearly 20%.

Zeltia Reports Earnings Results for the Nine Months Ended September 2013

Zeltia booked a net profit of EUR 14.09 million (USD 19.5 million) for the January to September 2013 period, up 64.92% on the year. The growth came as a result of the concentration in the oncology business. Gross sales of its anticancer drug Yondelis increased by 17.5%. This increase was due to a large extent, to the restoration in May of the supply of the Caelyx drug, administered in a combination with Yondelis, which had not been available since September 2011. Net sales of Yondelis totalled EUR 53.2 million, up 7.2% Earnings before interest, tax, depreciation and amortization (EBITDA) reached EUR 21.7 million, against EUR 22 million in the same period a year earlier. The main contributor to the EBITDA performance was the oncology area. Total net debt was reduced by 13%.

Zeltia S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2013

Zeltia S.A. reported earnings results for the second quarter and six months ended June 30, 2013. For the quarter, the company's loss attributable to equity holders of the parent company was EUR 1.42 million compared to an income attributable to equity holders of the parent company of EUR 15.54 million for the same quarter ended June 30, 2012. Total revenue was EUR 41.03 million compared to EUR 61.51 million for the same quarter ended June 30, 2012. For the six months, the company's income attributable to equity holders of the parent company was EUR 14.40 million compared to EUR 11.27 million for the same period ended June 30, 2012. Total revenue was EUR 91.19 million compared to EUR 93.79 million for the same period ended June 30, 2012.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZLIXF:US $3.19 USD 0.00

ZLIXF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZLIXF.
View Industry Companies
 

Industry Analysis

ZLIXF

Industry Average

Valuation ZLIXF Industry Range
Price/Earnings 46.2x
Price/Sales 3.8x
Price/Book 10.3x
Price/Cash Flow 48.6x
TEV/Sales 3.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZELTIA SA, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.